Single-agent docetaxel in previously untreated non-small-cell lung cancer

ONCOLOGY

Volumn 11, Issue 7 SUPPL., 1997, Pages 17-21

  Rigas, James R ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ASTHENIA; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; FLUID RETENTION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RASH;

EID: 0030878725     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Diaz JF, Andreu IM: Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: Reversibility, lihgand stoichiometry, and competition. Biochemistry 32:2747-2755, 1993.
2. Vogal M, Hilsenbeck SG, Depenbrock H et al: Preclinical activity of Taxotere (RP 56976, NSC 628503) against freshly explanted-clonogenic human tumor cells: comparison with Taxol and conventional antineoplastic agents. Eur J Cancer 29A:2009-2014, 1993.
3. Arbuck SG, Canetta R, Onetto N, et al: Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 20(suppl 3).31-39, 1993.
4. Rose WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Monogr Natl Cancer Inst 15:47-53, 1993.
5. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991.
6. Chang AY, Kim K, Glick J, et al: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993.
7. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993.
8. Rigas JR: Docetaxel in stage III and IV non-small cell lung cancer. Eur J Cancer 31A(suppl 4):S18-S20, 1995.
9. Fossella FV, Lee JS, Berille J, et al: Summary of phase II data of docetaxel (Taxotere), an active agent in the first-line and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 22(suppl 4):22-29, 1995.
10. Fossella FY, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrence or metastatic non-small cell lung cancer. J Clin Oncol 12:1238-1244, 1994.
11. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12:1232-1237, 1994.
12. Burris HA, Eckardt J, Fields S, et al: Phase II trials of Taxotere in patients with non-small cell lung cancer (abstract 1116). Proc Am Soc Clin Oncol 12:335, 1993.
13. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small cell lung cancer. A phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70:384-387, 1994
14. Robinet G, Thomas P, Perol M, et al: Phase II study of Taxotere (docetaxel) in advanced metastatic non-small cell lung cancer (NSCLC) previously treated with platinum (abstract 458P). Ann Oncol 7(suppl 5):96, 1996.
15. Kath R, Blumenstengel K, Fricke HJ et al: Preliminary report of chemotherapy results with docetaxel in advanced non-small cell lung cancer (NSCLC) (abstract 473P). Ann Oncol 7(suppl 5):100, 1996.
16. Mattson K, Le Chevalier T, Stupp R, et al: Preliminary report of a phase IIstudy of docetaxel (Taxotere) in locally advancedor metastatic non-small cell lung cancer (NSCLC) (abstract 473P). Ann Oncol 7(suppl 5):90, 1996
17. Riva A, Fumoleau P, Roche H, et al: Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer patients (PTS) treated with Taxotere (T) (abstract 660). Proc Am Soc Clin Oncol 16:188a, 1997.
18. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994.
19. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909, 1995.